Flare Therapeutics partners with Simplicis to eliminate 'single-point-of-failure' risks in compound management
By adopting Simplicis Ledger™, Flare Therapeutics replaces manual 'human-babysitting' of data with automation-ready infrastructure to scale life sciences R&D
9 Mar 2026
Simplicis has announced that Flare Therapeutics has selected Simplicis Ledger™ as its primary compound and inventory management platform. The partnership marks a strategic shift for Flare Tx, moving away from fragile, person-dependent workflows toward a resilient, automated foundation for drug discovery.
As biotech teams remain lean, many organizations face 'operational fragility', where critical scientific data relies on a single individual or a web of manual workarounds. Flare Therapeutics recognized this bottleneck and chose Ledger™ to bridge the gap between physical inventory and digital automation.
Breaking the cycle of 'offline' data management prior to this implementation, Flare Tx’s workflows, including assay-ready plate production and acoustic dispensing required significant manual oversight and custom IT workarounds. These 'offline' processes created operational risks and hindered cross-training.
By implementing Ledger™ and Ledger™ Acoustic, Flare Tx has achieved:
- End-to-end transparency: Real-time alignment between inventory state and assay execution.
- Automation-ready workflows: Seamless integration with acoustic dispensing platforms, removing the need for manual file handling.
- Operational continuity: A unified system that allows for predictable workflow management and easier team-wide adoption.
“Flare Tx’s move reflects a broader biotech trend: the shift from brittle, workaround-driven systems to 'Scientific Infrastructure' that supports velocity,” said James Craven, Chief Commercial Officer at Simplicis. “Ledger™ was designed to remove the hidden friction between inventory, automation, and people.”